Community Practice Connections™: Leveraging Clinical Data and Trials to Inform Treatment for Patients With GVHD: An Expert Case-Based Discussion

Release Date: January 30, 2021
Expiration Date: January 30, 2022

Activity Overview

This online educational activity features expert faculty specializing in hematologic oncology and transplantation, presenting the most recent guidelines and criteria for diagnosing graft-vs-host disease (GVHD), biomarkers for risk stratification and diagnostic and prognostic indications, clinical data of therapeutic agents in development for chronic and acute GVHD, and novel therapeutic targets.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Incyte Corporation; Kadmon Corporation, LLC.; and Mallinckrodt Pharmaceuticals.

Target Audience

These activities are intended for hematologists, medical oncologists, and other health care professionals interested in the latest advances in the treatment of patients with GVHD. Fellows, researchers, nurses, nurse practitioners, physician assistants, and other health care professionals interested in the treatment of patients with GVHD are also invited to attend.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Review the pathogenesis and criteria for diagnosis, staging, and grading of GVHD
• Outline current strategies for prophylaxis of GVHD and treatments for acute GVHD and chronic GVHD
• Discuss emerging strategies for prophylaxis and management of GVHD
• Develop strategies for identifying, mitigating, and managing treatment-related toxicities of GVHD

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER^® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Faculty

James L. Ferrara, MD
Professor of Pediatrics, Medicine, Hematology, Medical Oncology, and Oncological Sciences
Icahn School of Medicine at Mount Sinai
New York, NY

Disclosures: Other: Patent for biomarkers of acute GVHD.

Carrie Lynn Kitko, MD
Associate Professor of Pediatrics
Ingram Professorship in Pediatric Oncology
Medical Director, Pediatric Stem Cell Transplantation Program
Vanderbilt University Medical Center
Nashville, TN

Disclosures: No relevant financial relationships with commercial interests to disclose.

Iskra Pusic, MD
Associate Professor
Department of Medicine, Oncology Division
Bone Marrow Transplantation & Leukemia
Washington University School of Medicine in St. Louis
St Louis, MO

Disclosures: Consultant: Incyte Corporation, Kadmon Corporation, Syndax Pharmaceuticals.

Robert Zeiser, MD
Professor of Medicine
Head, Section of Tumor Immunology and Immune Modulation
Department of Hematology, Oncology, and Stem Cell Transplantation
Medical Center - University of Freiburg
Freiburg, Germany

Disclosures: Consultant: Novartis Pharmaceuticals, Hoffmann-La Roche, Therakos.

The staff of Physicians' Education Resource^®, LLC (PER^®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.